Skip to main content
Clinical Trials/NCT05691231
NCT05691231
Enrolling by Invitation
N/A

Long-Term Assessment of the Safety and Performance of the NuVasive Simplify Disc at Two Levels

NuVasive2 sites in 1 country158 target enrollmentJanuary 18, 2023

Overview

Phase
N/A
Intervention
Not specified
Conditions
Cervical Disc Disease
Sponsor
NuVasive
Enrollment
158
Locations
2
Primary Endpoint
Clinical Composite Success Rate
Status
Enrolling by Invitation
Last Updated
4 months ago

Overview

Brief Summary

A prospective, multicenter post-market clinical follow-up study to evaluate the 10-year long-term safety and effectiveness of the Simplify Disc at two levels in subjects who were enrolled in the IDE study (NCT03123549) and/or post approval study (NCT04980378).

Registry
clinicaltrials.gov
Start Date
January 18, 2023
End Date
May 10, 2029
Last Updated
4 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
NuVasive
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subject was enrolled in the Simplify Disc IDE (NCT03123549) and/or PAS (NCT04980378) at a participating study site
  • Patient understands the conditions of enrollment and is willing sign an informed consent form to participate in the study

Exclusion Criteria

  • Subject had an SSI at the index level during the IDE study (NCT03123549) or the PAS (NCT04980378)
  • Subject was withdrawn or withdrew consent to participate in the IDE study (NCT03123549) or PAS (NCT04980378)

Outcomes

Primary Outcomes

Clinical Composite Success Rate

Time Frame: 10 years

Individual success is defined as at least a 15 point improvement in Neck Disability Index (NDI) Score at 120 months compared with baseline, maintenance or improvement in neurologic status at 120 months compared with baseline, no additional surgical procedure at the index level within 120 months, and the absence of a serious adverse event classified as implant-associated or implant/surgical procedure-associated within 120 months. A subject must meet each criterion to be considered an overall study success. NDI scale is reported in a range from 0 - 100, with 0 consistent with best ability to function and 100 with worst ability to function.

Secondary Outcomes

  • Disc height at each annual timepoint will be compared to baseline(10 years)
  • Range of motion (ROM) at each annual timepoint compared to baseline(10 years)
  • Dysphagia Handicap Index1 (DHI) at each annual timepoint compared to baseline(10 years)
  • Adjacent level disc degeneration (ALDD) at each annual timepoint will be compared to baseline(10 years)
  • Displacement or migration of the Simplify Disc at each annual timepoint will be compared to the post-op timepoint in the IDE study (NCT03123549)(10 years)
  • Rate of adverse events attributable to Simplify Disc, or use of additional NuVasive instruments, implants, or technologies at each annual timepoint(10 years)
  • Patient satisfaction and perceived effect at each annual timepoint(10 years)
  • Motor status at each annual timepoint compared to baseline(10 years)
  • SF-36® Health Survey at each annual timepoint compared to baseline(10 years)
  • Percentage of subjects meeting the minimal clinically important difference (MCID) for NDI at each annual timepoint(10 years)
  • Percentage of subjects meeting MCID for neck and arm pain questionnaire for each of the following pain locations: neck pain, arm pain, left arm pain, right arm pain.(10 years)
  • Sensory status at each annual timepoint compared to baseline(10 years)

Study Sites (2)

Loading locations...

Similar Trials